New Day Diagnostics LLC reinforces its commitment to early cancer intervention

New Day Diagnostics LLC has announced that it has entered into an asset purchase agreement with Epigenomics AG, a molecular diagnostics company focused on blood testing for the early detection of cancer. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon®, a screening tool for the non-invasive detection of colorectal cancer. This announcement follows New Day Diagnostics’ recent merger with EDP Biotech Corp.

“We began a mission nearly two decades ago to drive accessibility of cost-effective early detection products. The addition of Epi proColon expands the company portfolio to include a much needed non-invasive CRC screening test that is both affordable and convenient,” said Eric Mayer, CEO of New Day Diagnostics LLC. “And we are excited to explore additional possibilities for the methylated DNA biomarker in improving patient outcomes for other indications.”

New Day Diagnostics specializes in designing, developing, and bring to market diagnostic tests, and the Epigenomics assets would further enhance the company’s ability to develop and commercialize diagnostic tests for earlier intervention and improved patient outcomes.

Want the latest science news straight to your inbox? Become a SelectScience member for free today >>